TSHA
Taysha Gene Therapies Inc
4.60$
-2.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Taysha Gene Therapies Inc (TSHA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -40 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.0 | -1.7 | -2.5 | -6.7 | -20 | -22 | -23 | -32 | -40 | -41 | -33 | -29 | 14 | -20 | -19 | -18 | -16 | -20 | -22 | -22 | -18 | -22 | -20 | -24 | -27 | -41 | -40 | -132 | |
| – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 1.2 | |
| – | – | – | 1.3 | 2.0 | 3.6 | 4.5 | 5.1 | 5.0 | 5.3 | 4.1 | 4.5 | 4.1 | 1.7 | 2.2 | 2.0 | 2.0 | 3.2 | 3.3 | 3.4 | 3.2 | 3.3 | 3.2 | 3.3 | 3.5 | 5.5 | 5.8 | 18 | |
| – | 2.8 | 4.3 | 4.3 | 5.0 | 9.1 | 4.7 | 6.2 | 7.9 | 6.8 | 4.3 | 4.7 | 42 | 1.8 | 6.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | 0.9 | 1.5 | 4.0 | -6.5 | 0.9 | 13 | 12 | 2.0 | 2.0 | -4.2 | -7.6 | 28 | -5.0 | -0.8 | -7.4 | -4.8 | 0.3 | -4.3 | -5.9 | -2.6 | -4.6 | 2.2 | 4.0 | -7.1 | -4.7 | 4.8 | -2.9 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 6.1 | 0.5 | 8.5 | 4.0 | 8.5 | 11 | 8.1 | 3.0 | 2.3 | 3.9 | 0.0 | 3.5 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.4 | 0.0 | 0.1 | 0.3 | 3.0 | 0.0 | 3.4 | |
| – | -1.5 | -3.0 | 0.0 | -6.1 | -0.5 | -8.5 | -4.0 | -8.5 | -11 | -8.1 | -3.0 | 0.0 | -3.9 | 0.0 | -3.5 | 0.0 | -0.1 | -0.2 | 0.0 | 0.0 | -0.4 | 0.1 | 0.0 | -0.2 | -3.0 | 0.0 | -3.3 | |
| – | – | – | – | -1.3 | – | – | – | – | – | 12 | -0.1 | – | 0.1 | 0.5 | – | -0.4 | – | – | – | – | – | – | -0.2 | – | – | – | – | |
| – | 0.0 | 0.0 | 0.0 | 30 | 30 | 26 | 0.4 | 10.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | – | – | – | |
| – | 18 | 0.3 | 274 | -1.5 | -1.5 | 26 | 30 | 9.1 | -0.1 | 11 | -0.1 | 42 | -0.4 | 0.4 | 141 | -4.2 | 0.0 | 70 | 6.6 | -0.4 | -0.1 | 216 | 8.8 | 50 | 0.7 | 217 | 276 | |
| 0.0 | 16 | -5.1 | 267 | -27 | -23 | -31 | -6.0 | -40 | -52 | -30 | -32 | 54 | -24 | -18 | 119 | -20 | -20 | 49 | -15 | -19 | -22 | 196 | -15 | 23 | -43 | 176 | 140 | |
| – | -1.7 | -2.5 | -6.7 | -26 | -23 | -31 | -36 | -49 | -52 | -41 | -32 | 12 | -24 | -19 | -21 | -16 | -20 | -22 | -22 | -18 | -22 | -20 | -24 | -27 | -44 | -40 | -136 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.